RP 4010
Alternative Names: RP-4010Latest Information Update: 28 Nov 2023
At a glance
- Originator Rhizen Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action ORAI1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Gastrointestinal cancer; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Switzerland (PO)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Gastrointestinal-cancer in USA
- 28 Jun 2020 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Second-line therapy or greater) in Australia (PO)